Panacea Pharmaceuticals, Inc. was founded in 1999 and is based in Gaithersburg, Maryland. Panacea Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic and diagnostic products for cancer and diseases of the central nervous system. It focuses on the development of proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology, as well as neurodegenerative diseases such as stroke, Alzheimer's disease, and Parkinson's disease. The company’s products include PAN-22, a human anit-HAAH monoclonal antibody for treatment of hepatocellular carcinoma; PAN-622, a Toxin Conjugate to treat carcinoma of the bile duct; and PAN-811 for the treatment of ischemic stroke. In addition, it develops blood, serum, and tissue tests to diagnose and monitor breast, colorectal, lung, and prostate cancers, as well as gene expression test that predicts the response of patients with Chronic Myelogenous Leukemia to imatinib.

Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel. Pluristem Therapeutics Inc., a development stage bio-therapeutics company, engages in the research, development, and production of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders. It develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, and adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in the company’s proprietary PluriX three-dimensional bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. The company’s principal product under Phase I clinical trial is PLX-PAD for people suffering from peripheral artery disease. Its pre-clinical products include PLX-IBD for inflammatory bowel diseases; PLX-STROKE for ischemic strokes; PLX-BMT for bone marrow transplantation; and PLX-MS for multiple sclerosis. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007.

Isotechnika Pharma may have isolated a new drug to combat organ rejection. Lead drug candidate voclosporin could replace cyclosporine as the immunosuppressant of choice for organ transplant recipients and patients with autoimmune conditions. Studies indicate it is more effective and has fewer side effects than cyclosporine. Isotechnika is testing the drug for kidney transplant recipients and psoriasis. Minority shareholder Paladin Labs has signed on to develop and market the drug in certain markets. Its Isotechnika Diagnostics division sells "breathalyzer" tests to diagnose H. pylori infections, which cause chronic gastritis and ulcers.

The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated LDL (low-density lipoprotein, also known as "bad" cholesterol) levels. Its flagship products - experimental drugs AEGR-733 and AEGR-427 - are MTP (microsomal triglyceride transfer protein) inhibitors, drugs which block a protein that incites cholesterol production in the liver and intestine. Cutting LDL levels may add years to patients' lives but must be weighed against potential side effects such as fat accumulation in the liver, which can lead to inflammation, scarring, and cirrhosis.

Monogram Biosciences, Inc. Diagnostics company operates in the growing field of personalized medicine, creating laboratory tests that help doctors tailor treatments for infectious disease and cancer patients based on the patients' genetic traits. Its PhenoSense and GenSeq tests determine patients' drug resistance to various classes of HIV drugs. It has also introduced its Trofile assay, which helps doctors choose patients who will be responsive to a new class of HIV drugs called CCR5 antagonists. Monogram markets its products to doctors and reference laboratories (for patient treatment) and to drug researchers (for clinical trials). The company was acquired by LabCorp in 2009.

BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Birmingham, Alabama. BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The company has progressed two compounds into late-stage pivotal clinical trials comprising Peramivir, an anti-viral for influenza; and Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor forcutaneous T-cell lymphoma (CTCL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the United States Department of Health and Human Services (HHS).Forodesine has been granted Orphan Drug status by the FDA for three indications, including T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias, such as T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-ALL. BioCryst Pharmaceuticals is also testing BCX4208, a second generation PNP inhibitor, which is in a Phase II study for the treatment of gout. The company utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. It has strategic alliances with the U.S. Department of Health and Human Services; Shionogi & Co., Ltd.; Green Cross Corporation; and Mundipharma International Holdings Limited.

ActivX Biosciences figures that the more you know about protein kinases, the easier it will be to inhibit them. That's the basis of its main product: a platform to profile protein kinases -- enzymes that regulate cell's signaling pathways. Its KiNativ platform has been launched for use by pharmaceutical and biotechnology companies as they develop the kinase inhibitors expected to make drug breakthroughs. The company also has its own pipeline of drug candidates in development, including one in trials for the treatment of Type-2 diabetes. Japanese drugmaker Kyorin Pharmaceutical, with whom ActivX had collaborated since 2002, bought the company in 2005 for $21 million.

Upsher-Smith Laboratories, Inc. was founded in 1919 and is headquartered in Minneapolis, Minnesota with a facility in Denver, Colorado. Upsher-Smith Laboratories, Inc., a pharmaceutical company, engages in developing, manufacturing, commercializing, marketing, and distributing prescription and over-the-counter products. It offers drugs for cardiology, women's health, dermatology, neurology, and epilepsy and Parkinson's diseases. The company also provides prenatal vitamins. It serves patients, physicians, pharmacists, and healthcare organizations.

Evotec AG (Evotec) is a drug discovery and development company focused on small molecule therapeutics. Evotec is developing treatments for diseases in the areas of neuroscience, pain, and inflammation. Evotec’s portfolio comprises five clinical drug candidates: EVT 101, a subtype selective NMDA receptor antagonist with potential for the treatment of Alzheimer’s disease, pain and depression, EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 302, a MAO-B inhibitor in development for smoking cessation, a P2X7 antagonist for the treatment of inflammatory diseases, and a small molecule vanilloid receptor (VR1) antagonist for the treatment of pain in partnership with Pfizer. Evotec’s late stage preclinical research programs focus on EVT 103, a back-up compound to EVT 101, H3 antagonists for the treatment of cognitive disorders and/or sleep, as well as antagonists for the purinergic receptor P2X3 for the treatment of pain.

Opko Health Inc. is a specialty healthcare company. The Company is focused on the discovery, development and commercialization of pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis and management of ophthalmic diseases and conditions. Its business consists of the development of ophthalmic pharmaceuticals and the development, commercialization and sale of ophthalmic diagnostic and imaging systems and instrumentation products. It focuses on exploring opportunities to acquire complementary pharmaceuticals, compounds, and technologies, which could, individually or in the aggregate, materially increase the scale of the Company’s business. On May 6, 2008, the Company completed the acquisition of Vidus Ocular, Inc. (Vidus).

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.